Mutation Recovery & Enrichment
Mutation-bearing EVs and cfDNA were spiked alone and together into healthy donor plasma and processed
with SeleCTEV¢â and Competitor Q to obtain DNA. SeleCTEV¢â isolated more mutation thank Competitor Q
from both biological sources, suggesting that SeleCTEV¢â is a more efficient way to isolate EVs and cfDNA
than Competitor Q.
Case Study: Metastatic Melanoma Patients

|
Plasma samples were collected from twenty patients
with BRAF V600E positive tumors and thirty patients
with wild type (WT) metastatic melanoma (MM) based
on tissue biopsy examination. Five hundred microliters
of plasma were processed with SeleCTEV¢â and
Competitor Q and copies of BRAV V600E and BRAF WT
were detected by digtal PCR. BRAF V600E gene copies
were detected in 11 - and 8 Competitor Q - processed
plasma samples of the mutant cohort. On average,
SeleCTEV¢â isolated moremutant and WT copies than
Competitor Q.
|

SeleCTEV¢â and Competitor Q were used for monitoring BRAFV600E levels in the plasma of BRAF inhibitor-
treated MM patients. In patient #1 disease progression (DP) occurred within 3 months and was associated to
rebounding levels of circulating BRAFV600E and unfavorable prognosis. In patient #2 no clinical evidence of
disease progression was observed at later time points, and mutant gene copies remained low or
undetectable in plasma.
Data Sheet (PDF)
|